Ask AI
HER2 Positive EBC

CE / CME

Evolving Treatment Landscape for HER2-Positive/HER2-Low Early Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: May 01, 2026

Expiration: October 31, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Jatoi I, Sung H, Jemal A. The emergence of the racial disparity in U.S. breast-cancer mortality. N Engl J Med. 2022; 386:2349.
  2. Zhao F, Copley B, Niu Q, et al. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021;185:841.
  3. Torres Sodipo MO, Hopkins MF, et al. Racial differences in breast cancer survival between black and white women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42:3867.
  4. Jackson I, Lei X, Zhao H, et al. Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer. NPJ Breast Cancer. 2025;11:138.
  5. Vaynrub A, Mishalani L, Raikhelkar, et al. Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer. Cardiooncology. 2024;10:68.
  6. Stabellini N, Cullen J, Cao L, et al. Racial disparities in breast cancer treatment patterns and treatment related adverse events. Sci Rep. 2023;13:1233.
  7. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.2.2026.
  8. Cazzaniga ME, Costa L, Freyer G, et al. risk factors for disease recurrence in patients with HER2+ early breast cancer and implications for therapy: a narrative review. Oncol Ther. 2025;14:95.
  9. Wali AF, El-Tanani M, Talath S, et al. Antibody-drug conjugates and beyond: next-generation targeted therapies for breast cancer. Cancers (Basel). 2025;17:3943.
  10. Bouwer NI, Jager A, Liesting C, et al. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: a review and implications for clinical practice. Breast. 2020;52:33.
  11. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895.
  12. Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2025.
  13. Ado-trastuzumab emtansine [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2025.
  14. Trastuzumab [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2024.
  15. Pertuzumab [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2025.
  16. Cortes-Funes H, Mendiola C, Manso L, et al. Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer. Breast Cancer Res. 2009;11(Suppl 1)S19.
  17. Neratinib [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc.; 2025.
  18. Holmes FA, Moy B, Delaloge S, et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.  Eur J Cancer. 2023;84:48-59.
  19. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122.
  20. Loibl S, Park YH, Shao Z, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2026;394:845.
  21. Tung NM, Tolaney SM, Lin NU, et al. Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. J Clin Oncol. 2025;43:501
  22. Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2026;37:166-179.
  23. Gao HF, Ye GL, Lin Y, et al. Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: the randomized noninferiority phase III neoCARHP trial. J Clin Oncol. 2026; [Epub].
  24. The ASCO Post. Preoperative THP leads to pCR in two-thirds of patients with early-stage HER2-positive ER-negative breast cancer. ascopost.com/news/june-2025/preoperative-thp-leads-to-pcr-in-two-thirds-of-patients-with-early-stage-her2-positive-er-negative-breast-cancer/. Accessed April 27, 2026.
  25. Jafari L, Akhter N.  Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrarive review. Breast Cancer Res Treat. 2021;186:295.
  26. Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res. 2019;175:595.
  27. Buono G, Deleuze A, Klocker EV, et al. 237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry. esmoopen.com/article/S2059-7029(23)00651-8/fulltext#:~:text=One%20third%20of%20ABC% 20pts,those%20outcomes%20in%20elderly%20patients. Accessed April 27, 2026.
  28. Schubbe D, Yen RW, Leavitt H, et al. Implementing shared decision making for early-stage breast cancer treatment using a coproduction learning collaborative: the SHAIR Collaborative protocol. Implement Sci Commun. 2023;4:79.
  29. Chae H, Ji H, Moon H, et al. Shared decision-making for early-stage breast cancer treatment: An evolutionary concept analysis. Asia Pac J Oncol Nurs. 2025;12:100775.
  30. Niranjan SJ, Martin MY, Fouad MN, et al. Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials. Cancer. 2020.26;1958.